Xenora Minerals Limited (XRA) Fair Value & Analysis
Basic Materials · AU · Market cap A$11.0M
Fair value as of: Jul 19, 2026
From 1 valuation models · updated yesterday
Share price −29.4% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.1000 – A$0.4050 · fair‑value band A$0.0085 – A$0.0170 · the A$0.1800 price screens above the A$0.0170 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Xenora Minerals Limited (XRA) currently trades at A$0.1800, while our model-based Fair Value estimate is A$0.0170, implying the stock looks roughly 90.6% overvalued today. We read business quality at 28/100 (below-average quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at A$172K. It earns a return on equity of -23.9%. The balance sheet holds a net cash position of A$1.1M. Fundamentals as of Jul 19, 2026
Our scenario range runs from A$0.0085 (bear case) to A$0.0170 (bull case); at A$0.1800, the current price sits above that range. The share trades about 58% below its 52-week high and 157% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -36% fair-value upside, at -91%, XRA screens richer than that median.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Xenora Minerals Limited engages in exploration and evaluation of mineral resources in Australia and Canada. It explores for gold, uranium, lithium, copper, zinc, lead, nickel, base, and precious metals deposits. The company was formerly known as Trinex Minerals Limited and changed its name to Xenora Minerals Limited in September 2025. Xenora Minerals Limited was incorporated in 2014 and is based in Subiaco, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Xenora Minerals Limited reported revenue of A$32.6K in FY2025 versus A$107K in FY2023, a compound −44.7%/yr. Reported net income was −A$6.9M in FY2025.
Is XRA fairly valued? → Check now
Similar stocks
10 more Other Industrial Metals & Mining stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BHP Group BHPLF | $44.00 | $23.74 | -46% |
| Rio Tinto Group RTNTF | $120.75 | $77.09 | -36% |
| Grupo México, S.A. GMBXF | $12.66 | $9.58 | -24% |
| CMOC Group CMCLY | $148.88 | $120.33 | -19% |
| Vale S.A VALE | $15.71 | $9.14 | -42% |
| Anglo American plc AAUKF | $51.51 | $20.30 | -61% |
| Fortescue Ltd FSUMF | $13.50 | $15.72 | +16% |
| China Tungsten And Hightech Materials Co 000657 | ¥108.33 | ¥10.89 | -90% |
| Hindustan Zinc Limited HINDZINC | ₹547.55 | ₹625.07 | +14% |
| China Northern Rare Earth (Group) High-Tech Co 600111 | ¥54.15 | ¥6.74 | -88% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Xenora Minerals Limited (XRA) undervalued?
What is the fair value of XRA?
What is the quality score of XRA?
What is the revenue of Xenora Minerals Limited (XRA)?
What is the net profit margin of XRA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when Xenora Minerals Limited reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of Xenora Minerals Limited materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.